(172) Substituting PEG-Lipid with Amphiphilic Polycarbonates in mRNA-Loaded Lipid Nanoparticles

Introduction: As the most clinically advanced formulations for mRNA delivery, lipid nanoparticles (LNPs) have gained traction with its impressive success of COVID-19 vaccines [1]. PEGylated lipid, a crucial component of LNPs, extends their systemic circulation by facilitating the particle stability in blood and avoiding the sequestration by mononuclear phagocyte system [2,3]. The polycarbonate-lipid hybrid mRNA nanoparticles (PC-HNPs) in this study were created by replacing ALC-0159, a PEG-lipid utilized in Pfizer-BioNTech's BNT162b2 vaccine with amphiphilic PEG-polycarbonate (PEG-PC) diblock copolymers.

Chuan Yang – Principal Scientist I, Bioprocessing Technology Institute, A*STAR, the Republic of Singapore; Yue Zhang – Scientist, Bioprocessing Technology Institute, A*STAR, the Republic of Singapore; Gui Zhao – Scientist, Bioprocessing Technology Institute, A*STAR, the Republic of Singapore; Melgious Ang – Scientist, Bioprocessing Technology Institute, A*STAR, the Republic of Singapore; Ki Hyun Bae – Senior Scientist II, Bioprocessing Technology Institute, A*STAR, the Republic of Singapore; James Hoi Po Hui – Professor, Yong Loo Lin School of Medicine, National University of Singapore, Republic of Singapore; James Hedrick – Scientist, IBM Almaden Research Center, USA; Yi Yan Yang – Distinguished Principal Scientist, Bioprocessing Technology Institute, A*STAR, the Republic of Singapore & Yong Loo Lin School of Medicine, National University of Singapore, Republic of Singapore